Kymera Therapeutics (KYMR) Total Non-Current Liabilities (2020 - 2024)

Kymera Therapeutics (KYMR) has reported Total Non-Current Liabilities for 5 consecutive years, with $142.4 million the latest figure, recorded in Q4 2024.

• In Q4 2024, Total Non-Current Liabilities fell 21.22% year-over-year to $142.4 million; the TTM figure through Dec 2024 stood at $142.4 million (down 21.22% YoY), while the FY2024 annual figure was $142.4 million, down 21.22% from the prior year.
• Total Non-Current Liabilities slipped to $142.4 million in Q4 2024 per KYMR's latest filing, from $180.8 million in the prior quarter.
• Across five years, Total Non-Current Liabilities topped out at $203.2 million in Q4 2020 and bottomed at $112.7 million in Q4 2022.
• Historically, Total Non-Current Liabilities has averaged $153.5 million across 5 years, with a median of $149.0 million in 2023.
• Annual changes were most pronounced in 2022 — Total Non-Current Liabilities decreased 29.14% — and 2023, when it jumped 60.37%.
• Kymera Therapeutics' Total Non-Current Liabilities stood at $203.2 million in 2020, then declined by 28.05% to $146.2 million in 2021, then slipped by 22.89% to $112.7 million in 2022, then surged by 60.37% to $180.8 million in 2023, then dropped by 21.22% to $142.4 million in 2024.
• Business Quant data shows KYMR's Total Non-Current Liabilities at $142.4 million in Q4 2024, $180.8 million in Q4 2023, and $156.8 million in Q3 2023.